Trial Profile
A double-blind, placebo-controlled, proof-of-concept clinical study assessing the effect of ACP-103 on deep, or slow wave, sleep in healthy older volunteers.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 May 2016
Price :
$35
*
At a glance
- Drugs Pimavanserin (Primary)
- Indications Insomnia
- Focus Proof of concept; Therapeutic Use
- 06 May 2016 New trial record.